A Study of LY2801653 in Advanced Cancer

Parts C and D were added to the registration in November, 2013, per protocol amendment. Parts
E and F were added to the registration in February, 2015, per protocol amendment.

Inclusion Criteria:

- Part A- Diagnosed with advanced and/or metastatic cancer during dose escalation

- Part B- Diagnosed with adenocarcinoma of the colon or rectum, head and neck squamous
cell carcinoma, uveal melanoma with liver with metastasis, or cholangiocarcinoma

- Part C - Diagnosed with head and neck squamous cell carcinoma and have received at
least one prior platinum-based systemic therapy

- Part D - Diagnosed with cholangiocarcinoma and have not received more than 1 prior
systemic therapy

- Part E - Diagnosed with cholangiocarcinoma, either intrahepatic or extrahepatic, that
is unresectable, recurrent, or metastatic. Participants must not have received prior
systemic front line therapy for metastatic or resectable disease (i.e. participants
may have received adjuvant gemcitabine but have not yet received gemcitabine/cisplatin
for recurrent metastatic disease). Participants must be, in the opinion of the
investigator, an appropriate candidate for experimental therapy. Participants should
be evaluated for the need to undergo biliary drainage by stent placement prior to
study participation. Participants should have adequate biliary drainage with no
unresolved biliary obstruction.

- Part F - Histologically- or cytologically-confirmed gastric carcinoma, including
gastric adenocarcinoma or gastroesophageal junction (GEJ) adenocarcinoma (participants
with adenocarcinoma of the distal esophagus are eligible if the primary tumor involves
the GEJ). Participants must be ramucirumab naïve. Participants must be, in the opinion
of the investigator, an appropriate candidate for experimental therapy. human
epidermal growth factor receptor 2 (HER2)/neu status should be documented, if known.

- Must be at least 18 years of age

- Adequate hematologic, renal, and liver functions

- Eastern Cooperative Oncology Group (ECOG) status of 0 or 1

- Ability to swallow capsules, with the exception of head and neck squamous cell
carcinoma participants who may have study drug crushed and administered through a
feeding tube

Exclusion Criteria:

- Have serious preexisting medical conditions that would preclude participation in the
study

- Have a chronic underlying infection

- Have symptomatic central nervous system (CNS) malignancy or metastasis

- Have current acute or chronic leukemia

- Are pregnant or lactating

- Have hepatocellular cancer, liver cirrhosis with a Child-Pugh stage of B or higher, or
have received a liver transplant

- Have a history of congestive heart failure with a New York Heart Association class
greater than 2, unstable angina, recent myocardial infarction (within 6 months of
study enrollment), transient ischemic attacks, stroke, or arterial or venous vascular
disease

- Have a QTc interval greater than 470 msec

- For participants in Part B, C, D, E, and F, a tumor tissue sample is mandatory, when
safe and feasible, for biomarker analysis